Business · 23/01/2024Updated: 10/17/2026 · 1 min read
FDA Approves Product Redeeming Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved a product, ZEPOSIA (ozanimod), that redeems a priority review voucher for a rare pediatric disease, following a review of its supplemental application submitted on May 27, 2021.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →